Repare Therapeutics’ RP-3500 Shows Potential of ATR Inhibitors in Precision Oncology
November 4, 2021 11:09 amby Alison Kanski
NEW YORK – Pharma companies are racing to develop oral ATR inhibitors that present a unique pan-cancer market opportunity.
Researchers reported positive Phase I results on one of these drugs, Repare Therapeutics’ RP3500, last month across tumor … Read more